Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Emisphere and Elan Announce Successful Completion of Additional Clinical Trials for Oral Heparin Preparation; Joint Venture Will Also Develop Oral Low Molecular Weight Heparin Product
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML
Toggle Summary Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements
Emisphere and Lilly Announce Expansion of Collaboration, and Execution of Two License Agreements Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with
View HTML
Toggle Summary Emisphere Reports 1998 Second Quarter and Six Month Financial Results
Emisphere Reports 1998 Second Quarter and Six Month Financial Results Hawthorne, NY, March 19, 1998 --- Emisphere Technologies, Inc. (Nasdaq: NMS:EMIS) today reported a net loss of approximately $2.6 million, or $0.25 per share, for the second quarter ended January 31, 1998, as compared to net loss
View HTML
Toggle Summary Emisphere Announces $13.5 Million Private Placement
Emisphere Announces $13.5 Million Private Placement Hawthorne, NY, May 4, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the closing of a $13.5 million private placement of 5% senior convertible notes. Emisphere plans to use the proceeds of the private placement for general
View HTML
Toggle Summary Emisphere Announces New Senior Vice President of Clinical Affairs
Emisphere Announces New Senior Vice President of Clinical Affairs Hawthorne, NY, May 20, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Barry B. Kanarek, M.D., Ph.D., has joined the Company as Senior Vice President of Clinical Affairs, a newly created position. Dr.
View HTML
Toggle Summary Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product
Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product Hawthorne, NY, May 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today it has initiated a Phase II clinical study for its oral heparin product for the prevention of deep vein thrombosis.
View HTML
Toggle Summary Emisphere Reports 1998 Third Quarter and Nine Month Financial Results
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML
Toggle Summary Emisphere and Elan Contribute $10 Million to Heparin Joint Venture
Emisphere and Elan Contribute $10 Million to Heparin Joint Venture Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral
View HTML
Toggle Summary Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials
Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials Indianapolis, IN, and Tarrytown, NY September 3, 1998 --- Eli Lilly & Co. (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) announced today that Lilly has formally selected a proprietary Emisphere carrier for
View HTML
Toggle Summary Emisphere Reports 1998 Fourth Quarter and Year End Financial Results
Emisphere Reports 1998 Fourth Quarter and Year End Financial Results Hawthorne, NY, October 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported fourth quarter and year end financial results for the period ended July 31, 1998. Net loss for the fourth quarter of 1998 was $3.4
View HTML

FOLLOW US